Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Zoe Donnellan"'
Autor:
Jane Harper, Katherine J Adams, Giovanna Bossi, Debbie E Wright, Andrea R Stacey, Nicole Bedke, Ruth Martinez-Hague, Dan Blat, Laure Humbert, Hazel Buchanan, Gabrielle S Le Provost, Zoe Donnellan, Ricardo J Carreira, Samantha J Paston, Luise U Weigand, Martina Canestraro, Joseph P Sanderson, Sophie Botta Gordon-Smith, Kate L Lowe, Karolina A Rygiel, Alex S Powlesland, Annelise Vuidepot, Namir J Hassan, Brian J Cameron, Bent K Jakobsen, Joseph Dukes
Publikováno v:
PLoS ONE, Vol 13, Iss 10, p e0205491 (2018)
Robust preclinical testing is essential to predict clinical safety and efficacy and provide data to determine safe dose for first-in-man studies. There are a growing number of examples where the preclinical development of drugs failed to adequately p
Externí odkaz:
https://doaj.org/article/c3d7165394b5442098ed39f7073a5fbd
Autor:
Emma Hickman, Luise U. Weigand, Debbie Baker, Linda Hibbert, Annelise Vuidepot, Namir J. Hassan, Zoe Donnellan, Samantha Paston, Louise Conlon, Giovanna Bossi, Joseph Dukes, Ruth Simmons, Ruth Ryan, Caroline Boudousquie, Alex Powlesland, Vanessa L. Clark, Bent K. Jakobsen, Kathy Hale
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Malignant cells may be recognised by T cells binding cell surface Class I HLA (Human Leukocyte Antigen)-peptide complexes presenting disease-associated epitopes. Many cancer patients have been shown to generate CD8 cytotoxic T cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40a79b68a41a341e39f5c9a1e1daf7d
https://doi.org/10.1186/2051-1426-3-s2-p380
https://doi.org/10.1186/2051-1426-3-s2-p380
Autor:
Marine C C Raman, Pierre J Rizkallah, Ruth Simmons, Zoe Donnellan, Joseph Dukes, Giovanna Bossi, Gabrielle S Le Provost, Penio Todorov, Emma Baston, Emma Hickman, Tara Mahon, Namir Hassan, Annelise Vuidepot, Malkit Sami, David K Cole, Bent K. Jakobsen
Publikováno v:
Scientific Reports
Natural T-cell responses generally lack the potency to eradicate cancer. Enhanced affinity T-cell receptors (TCRs) provide an ideal approach to target cancer cells, with emerging clinical data showing significant promise. Nevertheless, the risk of of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d72496433db148cb0f21ee07e265580f
https://pubmed.ncbi.nlm.nih.gov/26758806
https://pubmed.ncbi.nlm.nih.gov/26758806
Autor:
Namir J. Hassan, Tara Mahon, Emma Baston, Bent K. Jakobsen, Malkit Sami, Annelise Vuidepot, Zoe Donnellan, Peter Eamon Molloy, Brian Cameron, Jane Harper, Nathaniel Liddy, Joseph Dukes, Andrew M.F. Johnson, Giovanna Bossi, Samantha Paston
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Tumour-specific T cells have the potential to eradicate cancer. However anti-tumour immunity is limited by low TCR affinities, MHC downregulation by cancer cells and an immunosuppressive tumour microenvironment. As most tumour-assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0326ffe329d6cc8e1d5c2f28216ae2
http://europepmc.org/articles/PMC4649398
http://europepmc.org/articles/PMC4649398